Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis

The introduction of CDK4/6 inhibitors in combination with endocrine therapy (ET) represents the most relevant advance in the management of hormone receptor (HR) positive, HER2-negative metastatic breast cancer over the last few years. This meta-analysis of randomized controlled trials (RCTs) is aime...

Descripción completa

Detalles Bibliográficos
Autores principales: Piezzo, Michela, Chiodini, Paolo, Riemma, Maria, Cocco, Stefania, Caputo, Roberta, Cianniello, Daniela, Di Gioia, Germira, Di Lauro, Vincenzo, Rella, Francesca Di, Fusco, Giuseppina, Iodice, Giovanni, Nuzzo, Francesco, Pacilio, Carmen, Pensabene, Matilde, Laurentiis, Michelino De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503849/
https://www.ncbi.nlm.nih.gov/pubmed/32899139
http://dx.doi.org/10.3390/ijms21176400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503849/
https://www.ncbi.nlm.nih.gov/pubmed/32899139
http://dx.doi.org/10.3390/ijms21176400

Ejemplares similares